3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lung Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Meningeal Neoplasms
1
Melanoma
1
Lymphoma
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
12
Carboplatin
11
Specimen Handling
9
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Capecitabine
5
Biopsy
5
Nivolumab
4
Cyclophosphamide
4
sacituzumab govitecan
3
Gemcitabine
3
Fulvestrant
3
olaparib
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Taxes
2
Letrozole
2
Epirubicin
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
veliparib
1
trastuzumab deruxtecan
1
pyrotinib
1
pertuzumab
1
patritumab deruxtecan
1
omega-N-Methylarginine
1
naxitamab
1
lenvatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
sapanisertib
×
30 days
×
Clear all
No trials found.